Newsfeeds - Spark Newswire

1 minute read

Goldman Sachs Initiates Coverage On Codiak BioSciences with Buy Rating, Announces Price Target of $19

Today, 3:51 AM

Goldman Sachs analyst Andrea Tan initiates coverage on Codiak BioSciences (NASDAQ:CDAK) with a Buy rating and announces Price Target of $19.

CDAK

1 minute read

Trading Ideas

‘3 Stocks That Are Flirting With a Bottom; Analysts Say ‘Buy” -Tip Ranks Report

By Benzinga Newsdesk

Today, 3:51 AM

https://www.tipranks.com/news/article/3-stocks-that-are-flirting-with-a-bottom-analysts-say-buy-3/

CDAK

1 minute read

Codiak BioSciences Q3 EPS $(0.97) Up From $(12.83) YoY, Sales $1.16M Up From $954.00K YoY

By Benzinga Newsdesk

Today, 3:51 AM

Codiak BioSciences (NASDAQ:CDAK) reported quarterly losses of $(0.97) per share. This is a 92.44 percent increase over losses of $(12.83) per share from the same period last year. The company reported $1.16 million in

CDAK

1 minute read

Sarepta, Codiak Nix Exosome Therapy Development Pact

By Vandana Singh

Today, 3:51 AM

Sarepta Therapeutics Inc (NASDAQ:SRPT) notified Codiak BioSciences Inc (NASDAQ:CDAK) that it would terminate the two-year Research License and Option agreement early. The termination…

CDAK

8 minute read

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs

By Shanthi Rexaline

Today, 3:51 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)

ABIO

2 minute read

Codiak To Present Preclinical Data Demonstrating New Potential Therapeutic Applications Of Engineered Exosomes At Society For Immunotherapy Of Cancer (SITC) Annual Meeting

By Benzinga Newsdesk

Today, 3:51 AM

Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that three posters

CDAK

1 minute read

Legal
News

Codiak BioSciences Files For U.S. Patent Titled ‘METHODS OF SUPPRESSING DELIVERY OF EXOSOMES TO LIVER AND SPLEEN’

By Benzinga Newsdesk

Today, 3:51 AM

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=7658&p=154&f=G&l=50&d=PG01&S1=20210923.PD.&OS=PD/20210923&RS=PD/20210923

CDAK

6 minute read

84 Biggest Movers From Friday

By Lisa Levin

Today, 3:51 AM

Gainers

ACOR

1 minute read

Codiak BioSciences Q2 EPS $(0.99), Sales $890.00K Up From $187.00K YoY

By Benzinga Newsdesk

Today, 3:51 AM

Codiak BioSciences (NASDAQ:CDAK) reported quarterly losses of $(0.99) per share. The company reported $890.00 thousand in sales this quarter. This is a 375.94 percent increase over sales of $187.00 thousand the same

CDAK

0 minute read

Uncategorized

Codiak Biosciences Shares Resume Trade Following Circuit Breaker, Stock Up 22.6%

By Benzinga Newsdesk

Today, 3:51 AM

CDAK